JP2009511426A - ミネラルおよび骨格代謝の調節 - Google Patents

ミネラルおよび骨格代謝の調節 Download PDF

Info

Publication number
JP2009511426A
JP2009511426A JP2008529121A JP2008529121A JP2009511426A JP 2009511426 A JP2009511426 A JP 2009511426A JP 2008529121 A JP2008529121 A JP 2008529121A JP 2008529121 A JP2008529121 A JP 2008529121A JP 2009511426 A JP2009511426 A JP 2009511426A
Authority
JP
Japan
Prior art keywords
composition
pth
levels
patient
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008529121A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009511426A5 (https=
Inventor
トーマス ハーバーバーガー
デイビッド ローゼン
是成 熊谷
Original Assignee
アコロジックス インコーポレイティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アコロジックス インコーポレイティッド filed Critical アコロジックス インコーポレイティッド
Publication of JP2009511426A publication Critical patent/JP2009511426A/ja
Publication of JP2009511426A5 publication Critical patent/JP2009511426A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008529121A 2005-08-30 2006-08-23 ミネラルおよび骨格代謝の調節 Pending JP2009511426A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71315405P 2005-08-30 2005-08-30
US71711505P 2005-09-13 2005-09-13
US80779706P 2006-07-19 2006-07-19
PCT/US2006/033133 WO2007027510A2 (en) 2005-08-30 2006-08-23 Regulation of mineral and skeletal metabolism

Publications (2)

Publication Number Publication Date
JP2009511426A true JP2009511426A (ja) 2009-03-19
JP2009511426A5 JP2009511426A5 (https=) 2009-07-30

Family

ID=37809379

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008529121A Pending JP2009511426A (ja) 2005-08-30 2006-08-23 ミネラルおよび骨格代謝の調節

Country Status (6)

Country Link
US (6) US20070066514A1 (https=)
EP (1) EP1937064A4 (https=)
JP (1) JP2009511426A (https=)
AU (1) AU2006285127A1 (https=)
CA (1) CA2621167A1 (https=)
WO (1) WO2007027510A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
ES2729051T3 (es) * 2009-07-29 2019-10-30 Kai Pharmaceuticals Inc Agentes terapéuticos para reducir los niveles de hormona paratiroidea
US9265097B2 (en) * 2010-07-01 2016-02-16 Goji Limited Processing objects by radio frequency (RF) energy
CN103857405B (zh) 2011-06-08 2015-12-02 凯伊药品公司 用于调节血清磷的治疗剂
RU2730997C1 (ru) * 2020-03-10 2020-08-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ диагностики первичного гиперпаратиреоза
RU2730999C1 (ru) * 2020-03-10 2020-08-26 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ биохимической диагностики первичного гиперпаратиреоза

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5384313A (en) * 1993-11-24 1995-01-24 Wisconsin Alumni Research Foundation 21-norvitamin D compounds
MXPA00011272A (es) * 1998-05-18 2003-04-22 Univ London Una novedosa fosfatonina de hormona polipeptida.
US6673900B2 (en) * 1999-11-04 2004-01-06 University College London Polypeptide hormone-phosphatonin
AU782304B2 (en) * 1999-09-02 2005-07-14 Acologix, Inc. Methods and compositions for reducing serum phosphate levels
US6790639B2 (en) * 2000-02-29 2004-09-14 Pfizer Inc. Mammalian osteoregulins
US6264987B1 (en) * 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
WO2001098495A1 (fr) * 2000-06-21 2001-12-27 Takeda Chemical Industries, Ltd. Nouvelle proteine et son adn
US20040048837A1 (en) * 2002-09-06 2004-03-11 Lazarus J. Michael Method for treatment of renal disease
US20070099822A1 (en) * 2003-09-19 2007-05-03 Rowe Peter S Regulation of tissue mineralization and phosphate metabolism by asarm peptides

Also Published As

Publication number Publication date
CA2621167A1 (en) 2007-03-08
EP1937064A4 (en) 2009-09-16
WO2007027510A3 (en) 2008-01-10
EP1937064A2 (en) 2008-07-02
US20110251124A1 (en) 2011-10-13
US20090018064A1 (en) 2009-01-15
WO2007027510A2 (en) 2007-03-08
US20090023633A1 (en) 2009-01-22
AU2006285127A8 (en) 2008-07-24
US20090029915A1 (en) 2009-01-29
AU2006285127A1 (en) 2007-03-08
US20090023634A1 (en) 2009-01-22
US20070066514A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
US12358976B2 (en) Methods for increasing serum concentration of phosphorous and/or 1,25-hydroxy vitamin d
JP7209382B2 (ja) 心不全の治療用組成物
Hoenderop et al. Epithelial Ca2+ and Mg2+ channels in health and disease
Quinn et al. Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo
Tay et al. Optimal dosing and delivery of parathyroid hormone and its analogues for osteoporosis and hypoparathyroidism–translating the pharmacology
JP2023144124A (ja) 骨格異形成症を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用
JP5941040B2 (ja) 副甲状腺ホルモン類似体およびその使用
Marcucci et al. Phosphate wasting disorders in adults
US20110251124A1 (en) Regulation of mineral and skeletal metabolism
US20030109537A1 (en) Methods and materials for treating bone conditions
KR20220045206A (ko) 연장 방출형 조성물을 위한 소수성 펩티드 염
US20250032576A1 (en) CNP Therapy
EP3415527B1 (de) Verwendung der extrazellulären domäne des transferrinrezeptor 2 zur diagnostik und behandlung von primär und sekundär sklerosierenden erkrankungen
LU100168B1 (en) Prevention of Bone and Mineral Disorders by Restoring Calcium and Phosphate Homeostasis in Patients Suffering from Chronic Kidney Disease
CN101282640A (zh) 矿物与骨骼代谢的调节
TW202535449A (zh) Ｃｎｐ變異體、其接合物及調配物
Scheinman et al. Quantitative evaluation of anticalciuretic effects of synthetic parathyroid hormonelike peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090612

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20101018